Laboratory Medicine ›› 2016, Vol. 31 ›› Issue (11): 969-973.DOI: 10.3969/j.issn.1673-8640.2016.011.010
• Orginal Article • Previous Articles Next Articles
ZHAN Wenli, LI Lixin, HUANG Zhuochun, HU Jing, WU Yongkang
Received:
2016-03-03
Online:
2016-11-30
Published:
2016-12-22
CLC Number:
ZHAN Wenli, LI Lixin, HUANG Zhuochun, HU Jing, WU Yongkang. Consistency of 2 systems for the determination of antinuclear antibody profile[J]. Laboratory Medicine, 2016, 31(11): 969-973.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2016.011.010
组别 | 例数 | 抗Sm抗体 | 抗RIB抗体 | 抗SS-A抗体 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
胡曼 | 欧蒙 | 胡曼 | 欧蒙 | 胡曼 | 欧蒙 | ||||||
SLE组 | 358 | 174(48.6) | 97(27.1) | 88(24.6) | 111(31.0) | 223(62.3) | 226(63.1) | ||||
SS组 | 47 | 4(8.5) | 0(0.0) | 1(2.1) | 2(4.3) | 47(100.0) | 47(100.0) | ||||
MCTD组 | 8 | 1(12.5) | 0(0.0) | 0(0.0) | 0(0.0) | 2(25.0) | 2(25.0) | ||||
OA组 | 6 | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | ||||
RA组 | 56 | 5(8.9 ) | 1(1.8) | 0(0.0) | 0(0.0) | 10(17.9) | 9(16.1) | ||||
SCL组 | 9 | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 3(33.3) | 1(11.1) | ||||
AS组 | 11 | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 1(9.1) | 1(9.1) | ||||
AIH组 | 10 | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 1(10.0) | 2(20.0) | ||||
正常对照组 | 47 | 3(6.4) | 0(0.0) | 0(0.0) | 0(0.0) | 2(4.3) | 5(10.6) | ||||
合计 | 552 | 187(33.9) | 98(17.8) | 89(16.1) | 113(20.5) | 289(52.4) | 311(53.1) | ||||
组别 | 抗SS-B抗体 | 抗Scl-70抗体 | 抗RNP抗体 | 抗Jo-1抗体 | |||||||
胡曼 | 欧蒙 | 胡曼 | 欧蒙 | 胡曼 | 欧蒙 | 胡曼 | 欧蒙 | ||||
SLE组 | 48(13.4) | 44(12.3) | 4(1.1) | 6(1.7) | 121(33.8) | 181(50.6) | 2(0.6) | 5(1.4) | |||
SS组 | 18(38.3) | 24(51.1) | 0(0.0) | 0(0.0) | 4(8.5) | 3(6.4) | 0(0.0) | 0(0.0) | |||
MCTD组 | 0(0.0) | 1(12.5) | 0(0.0) | 0(0.0) | 5(62.5) | 6(75.0) | 0(0.0) | 0(0.0) | |||
OA组 | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 1(16.7) | 0(0.0) | 0(0.0) | 0(0.0) | |||
RA组 | 4(7.1) | 2(3.6) | 0(0.0) | 0(0.0) | 1(1.8) | 1(1.8) | 0(0.0) | 0(0.0) | |||
SCL组 | 1(11.1) | 0(0.0) | 3(33.3) | 2(22.2) | 0(0.0) | 1(11.1) | 0(0.0) | 1(11.1) | |||
AS组 | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 1(9.1) | 0(0.0) | 0(0.0) | |||
AIH组 | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | |||
正常对照组 | 2(4.3) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | |||
合计 | 73(13.2) | 71(12.9) | 7(1.3) | 8(1.4) | 132(23.9) | 193(35.0) | 2(0.4) | 6(1.1) |
组别 | 例数 | 抗Sm抗体 | 抗RIB抗体 | 抗SS-A抗体 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
胡曼 | 欧蒙 | 胡曼 | 欧蒙 | 胡曼 | 欧蒙 | ||||||
SLE组 | 358 | 174(48.6) | 97(27.1) | 88(24.6) | 111(31.0) | 223(62.3) | 226(63.1) | ||||
SS组 | 47 | 4(8.5) | 0(0.0) | 1(2.1) | 2(4.3) | 47(100.0) | 47(100.0) | ||||
MCTD组 | 8 | 1(12.5) | 0(0.0) | 0(0.0) | 0(0.0) | 2(25.0) | 2(25.0) | ||||
OA组 | 6 | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | ||||
RA组 | 56 | 5(8.9 ) | 1(1.8) | 0(0.0) | 0(0.0) | 10(17.9) | 9(16.1) | ||||
SCL组 | 9 | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 3(33.3) | 1(11.1) | ||||
AS组 | 11 | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 1(9.1) | 1(9.1) | ||||
AIH组 | 10 | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 1(10.0) | 2(20.0) | ||||
正常对照组 | 47 | 3(6.4) | 0(0.0) | 0(0.0) | 0(0.0) | 2(4.3) | 5(10.6) | ||||
合计 | 552 | 187(33.9) | 98(17.8) | 89(16.1) | 113(20.5) | 289(52.4) | 311(53.1) | ||||
组别 | 抗SS-B抗体 | 抗Scl-70抗体 | 抗RNP抗体 | 抗Jo-1抗体 | |||||||
胡曼 | 欧蒙 | 胡曼 | 欧蒙 | 胡曼 | 欧蒙 | 胡曼 | 欧蒙 | ||||
SLE组 | 48(13.4) | 44(12.3) | 4(1.1) | 6(1.7) | 121(33.8) | 181(50.6) | 2(0.6) | 5(1.4) | |||
SS组 | 18(38.3) | 24(51.1) | 0(0.0) | 0(0.0) | 4(8.5) | 3(6.4) | 0(0.0) | 0(0.0) | |||
MCTD组 | 0(0.0) | 1(12.5) | 0(0.0) | 0(0.0) | 5(62.5) | 6(75.0) | 0(0.0) | 0(0.0) | |||
OA组 | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 1(16.7) | 0(0.0) | 0(0.0) | 0(0.0) | |||
RA组 | 4(7.1) | 2(3.6) | 0(0.0) | 0(0.0) | 1(1.8) | 1(1.8) | 0(0.0) | 0(0.0) | |||
SCL组 | 1(11.1) | 0(0.0) | 3(33.3) | 2(22.2) | 0(0.0) | 1(11.1) | 0(0.0) | 1(11.1) | |||
AS组 | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 1(9.1) | 0(0.0) | 0(0.0) | |||
AIH组 | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | |||
正常对照组 | 2(4.3) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | |||
合计 | 73(13.2) | 71(12.9) | 7(1.3) | 8(1.4) | 132(23.9) | 193(35.0) | 2(0.4) | 6(1.1) |
项目 | 阳性符合率(%) | 总体符合率(%) | Kappa值 | P值 |
---|---|---|---|---|
抗Sm抗体 | 15.2 | 79.9 | 0.550 | 0.000 |
抗RIB抗体 | 15.0 | 93.5 | 0.783 | 0.000 |
抗SS-A抗体 | 49.1 | 92.8 | 0.855 | 0.636 |
抗SS-B抗体 | 9.6 | 91.3 | 0.697 | 0.871 |
抗Scl-70抗体 | 1.0 | 99.2 | 0.662 | 1.000 |
抗RNP抗体 | 20.6 | 82.4 | 0.583 | 0.000 |
抗Jo-1抗体 | 0.2 | 98.9 | 0.246 | 0.219 |
项目 | 阳性符合率(%) | 总体符合率(%) | Kappa值 | P值 |
---|---|---|---|---|
抗Sm抗体 | 15.2 | 79.9 | 0.550 | 0.000 |
抗RIB抗体 | 15.0 | 93.5 | 0.783 | 0.000 |
抗SS-A抗体 | 49.1 | 92.8 | 0.855 | 0.636 |
抗SS-B抗体 | 9.6 | 91.3 | 0.697 | 0.871 |
抗Scl-70抗体 | 1.0 | 99.2 | 0.662 | 1.000 |
抗RNP抗体 | 20.6 | 82.4 | 0.583 | 0.000 |
抗Jo-1抗体 | 0.2 | 98.9 | 0.246 | 0.219 |
项目 | 例数 | 胡曼(+) 欧蒙(-) | 胡曼(-) 欧蒙(+) |
---|---|---|---|
抗Sm抗体 | 105 | 97(92.4) | 8(7.6) |
抗RIB抗体 | 36 | 6(16.7) | 30(83.3) |
抗RNP抗体 | 97 | 18(18.6) | 79(81.4) |
项目 | 例数 | 胡曼(+) 欧蒙(-) | 胡曼(-) 欧蒙(+) |
---|---|---|---|
抗Sm抗体 | 105 | 97(92.4) | 8(7.6) |
抗RIB抗体 | 36 | 6(16.7) | 30(83.3) |
抗RNP抗体 | 97 | 18(18.6) | 79(81.4) |
组别 | 例数 | 胡曼 | 欧蒙 |
---|---|---|---|
SLE组 | 358 | 174(48.6) | 97(27.1) |
非SLE组 | 194 | 13(6.7) | 1(0.5) |
组别 | 例数 | 胡曼 | 欧蒙 |
---|---|---|---|
SLE组 | 358 | 174(48.6) | 97(27.1) |
非SLE组 | 194 | 13(6.7) | 1(0.5) |
1 | PFAU JC,SERVE KM,NOONAN CW.Autoimmunity and asbestos exposure[J]. Autoimmune Dis,2014,2014:782045. |
2 | MAHLER M,FRITZLER MJ.Epitope specificity and significance in systemic autoimmune diseases[J]. Ann N Y Acad Sci,2010,1183:267-287. |
3 | HANLY JG,SU L,FAREWELL V,et al.Comparison between multiplex assays for autoantibody detection in systemic lupus erythematosus[J]. J Immunol Methods,2010,358(1-2):75-80. |
4 | ZAFRIR Y,GILBURD B,CARRASCO MG,et al.Evaluation of an automated chemiluminescent immunoassay kit for antinuclear antibodies in autoimmune diseases[J]. Immunol Res,2013,56(2-3):451-456. |
5 | ALMOGREN A,SHAKOOR Z,HASANATO RM,et al.Autoantibody detection:prevailing practices at a tertiary care hospital in Riyadh[J]. Clin Lab,2014,60(4):671-675. |
6 | CARO PEREZ A,KUMBLE S,KUMBLE KD,et al.Evaluation of a multiplex ELISA for autoantibody profiling in patients with autoimmune connective tissue diseases[J]. Autoimmune Dis,2014,2014:896787. |
7 | 刘春,马云,王彬. 4种检测试剂对350例临床标本ENA多肽抗体谱检测结果分析[J]. 国际检验医学杂志,2013,34(5):604-606. |
8 | 王兰兰,许化溪. 临床免疫学检验[M]. 5版. 北京:人民卫生出版社,2012:282-284. |
9 | DAMOISEAUX J,ANDRADE LE,FRITZLER MJ,et al.Autoantibodies 2015:from diagnostic biomarkers toward prediction,prognosis and prevention[J]. Autoimmun Rev,2015,14(6):555-563. |
10 | BHAGAT M,SEHRA ST,SHAHANE A,et al.Utility of immunologic testing in suspected rheumatologic disease[J]. Curr Allergy Asthma Rep,2014,14(1):405. |
11 | CONRAD K,ROGGENBUCK D,REINHOLD D,et al.Autoantibody diagnostics in clinical practice[J]. Autoimmun Rev,2012,11(3):207-211. |
12 | CARPINTERO MF,MARTINEZ L,FERNANDEZ I,et al.Diagnosis and risk stratification in patients with anti-RNP autoimmunity[J]. Lupus,2015,24(10):1057-1066. |
13 | TRIVEDI S,ZANG Y,CULPEPPER S,et al.T cell vaccination therapy in an induced model of anti-RNP autoimmune glomerulonephritis[J]. Clin Immunol,2010,137(2):281-287. |
14 | SHI ZR,CAO CX,TAN GZ,et al.The association of serum anti-ribosomal P antibody with clinical and serological disorders in systemic lupus erythematosus:a systematic review and meta-analysis[J]. Lupus,2015,24(6):588-596. |
15 | ARROYO-AVILA M,SANTIAGO-CASAS Y,MCGWIN G Jr,et al.Clinical associations of anti-Smith antibodies in PROFILE:a multi-ethnic lupus cohort[J]. Clin Rheumatol,2015,34(7):1217-1223. |
16 | REVEILLE JD.Predictive value of autoantibodies for activity of systemic lupus erythematosus[J]. Lupus,2004,13(5):290-297. |
17 | LI J,LENG X,LI Z,et al.Chinese SLE treatment and research group registry:Ⅲ. Association of autoantibodies with clinical manifestations in Chinese patients with systemic lupus erythematosus[J]. J Immunol Res,2014,2014:809389. |
18 | ARTIM-ESEN B,CENE E,SAHINKAYA Y,et al.Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center[J]. J Rheumatol,2014,41(7):1304-1310. |
19 | MAHLER M.Sm peptides in differentiation of autoimmune diseases[J]. Adv Clin Chem,2011,54:109-128. |
20 | 钟运华. SmD1蛋白表达与免疫原性研究及其抗体检测初步应用[D]. 广州:广州中医药大学,2014. |
21 | 庄健海,卓雪芽,黄声淳,等. 自身抗体检测对系统性红斑狼疮的诊断价值分析[J]. 检验医学与临床,2013,10(12):1557-1559. |
22 | 王奔放,郁建江,周剑波,等. 抗SmD1抗体在系统性红斑狼疮中的临床应用价值[J]. 临床和实验医学杂志,2012,11(3):168-169. |
23 | 欧萌萌,凌卫明,叶燕. 线性免疫法测定系统性红斑狼疮患者血清中抗SmD1、AnuA、抗P0和dsDNA抗体的意义[J]. 中国实验诊断学,2014,18(1):131-132. |
[1] | DUAN Lili, JIANG Chang, ZHOU Dongmei. Role of PLR in ankylosing spondylitis patients with positive antinuclear antibody [J]. Laboratory Medicine, 2023, 38(7): 669-674. |
[2] | SU Zhenzhen, ZOU Jihua, WANG Huimin, XU Weifeng, DING Fang, ZHANG Jingmei, WANG Zhanke. Consistency of serum LDL-P and LDL-C determination results [J]. Laboratory Medicine, 2023, 38(2): 148-152. |
[3] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
[4] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
[5] | YANG Xue, XU Chong, SONG Ying, ZHAO Qiang, MIAO Yingbo, WANG Qing, ZHOU Jing. Survey on the consistency of complete blood cell count results in three regions of the Yangtze River Delta,China [J]. Laboratory Medicine, 2022, 37(4): 387-391. |
[6] | JU Yinghui, MO Huifang, WU Hui, CHEN Pu, GUO Wei, WANG Beili. Performance comparison of lymphocyte subset determination by 6-color flow cytometry with 2 different reagents [J]. Laboratory Medicine, 2022, 37(3): 270-273. |
[7] | WANG Huiru, WANG Shenghua, HUANG Shanshan, WU Hao, YU Wenjing, GUO Yinghui. Patient medians and exponentially weighted moving average in comparing peripheral blood RBC count results of different instruments [J]. Laboratory Medicine, 2022, 37(11): 1093-1097. |
[8] | SUN Jiangman, MENG Xiangzhao, LI Min, SHAO Yan, YU Hongyuan. Optimization of serum uric acid reference measurement proceduce and application in conventional systems [J]. Laboratory Medicine, 2022, 37(10): 984-988. |
[9] | LÜ Xianmin, YU Guoqi, CHEN Zhengzheng, JIANG Lihua, YAN Luwei, FEI Xianming. Consistency of abnormal results before and after re-determinations based on K+,Na+ and total calcium determinations [J]. Laboratory Medicine, 2021, 36(8): 843-846. |
[10] | LU Yinhua, ZHU Yuqing, ZHAO Xiaojun, CAO Danru, ZHU Lingfeng, GU Zhidong. Consistency of the results of anti-HCV antibody gray zone samples among different determination systems [J]. Laboratory Medicine, 2021, 36(7): 700-704. |
[11] | ZHENG Cuiling, WANG Li, CHENG Yan, CUI Wei. Fresh blood comparison program in daily internal quality control of hematology analyzers [J]. Laboratory Medicine, 2021, 36(6): 662-666. |
[12] | CHEN Jianbo, YANG Yong, LI Huiyuan, REN Chanjun, DU Juan, LI Genshi, TAO Ran, CHEN Jingxian, ZHANG Ling, LI Miao. Comparison of 4 commercial kits for detecting SARS-CoV-2 nucleic acid [J]. Laboratory Medicine, 2021, 36(4): 396-399. |
[13] | TANG Chengfang, WEI Qingxiu, QIN Jianrong, TANG Fang, LIU Sichi, JIANG Xiang, HUANG Yonglan. Comparison of different-brand tandem mass spectrometers for newborn screening of genetic metabolic diseases [J]. Laboratory Medicine, 2021, 36(10): 1042-1046. |
[14] | LIU Zhangling, LI Juan, PU Ran, TANG Rongrui. Application of PDCA cycle in promoting mutual recognition of biochemical item determination results [J]. Laboratory Medicine, 2020, 35(9): 943-945. |
[15] | HE Yong, WANG Hui, LI Xiaoling, NIE Xin, JIANG Hong. Establishment and analysis of comparison methods among POCT blood gas analyzers [J]. Laboratory Medicine, 2019, 34(8): 758-762. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||